ATP13A2 — ATPase Cation Transporting 13A2

ATP13A2 — ATPase Cation Transporting 13A2 (PARK9)

Overview

ATP13A2 (also known as PARK9) encodes a P5B-type ATPase cation transporter that is primarily localized to lysosomal and late endosomal membranes [@kett2015]. This transmembrane protein is critically involved in maintaining cation homeostasis within the lysosomal lumen, particularly for manganese (Mn2+), zinc (Zn2+), and iron (Fe2+/Fe3+) [@tanaka2022]. ATP13A2 is highly expressed in brain regions vulnerable to neurodegeneration in Parkinson's disease (PD), including the substantia nigra pars compacta, basal ganglia, and cerebral cortex [@lefevre2018].

The gene was first implicated in neurodegenerative disease when homozygous loss-of-function mutations were identified as the cause of Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of parkinsonism [@schmitt2010]. Subsequent research has revealed that ATP13A2 plays broader roles in lysosomal function, autophagy, metal homeostasis, and neuronal survival—pathways central to the pathogenesis of both familial and sporadic PD. PMID: 41993310

Molecular Function

Lysosomal Cation Transport

ATP13A2 — ATPase Cation Transporting 13A2 (PARK9)

Overview

ATP13A2 (also known as PARK9) encodes a P5B-type ATPase cation transporter that is primarily localized to lysosomal and late endosomal membranes [@kett2015]. This transmembrane protein is critically involved in maintaining cation homeostasis within the lysosomal lumen, particularly for manganese (Mn2+), zinc (Zn2+), and iron (Fe2+/Fe3+) [@tanaka2022]. ATP13A2 is highly expressed in brain regions vulnerable to neurodegeneration in Parkinson's disease (PD), including the substantia nigra pars compacta, basal ganglia, and cerebral cortex [@lefevre2018].

The gene was first implicated in neurodegenerative disease when homozygous loss-of-function mutations were identified as the cause of Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of parkinsonism [@schmitt2010]. Subsequent research has revealed that ATP13A2 plays broader roles in lysosomal function, autophagy, metal homeostasis, and neuronal survival—pathways central to the pathogenesis of both familial and sporadic PD. PMID: 41993310

Molecular Function

Lysosomal Cation Transport

ATP13A2 belongs to the P-type ATPase family, specifically the P5B subfamily, which is characterized by the transport of transition metal cations across biological membranes. The primary physiological substrate of ATP13A2 appears to be manganese, although the protein can also transport zinc and potentially other cations [@kett2015]. Lysosomal manganese transport is essential for neuronal health because excess manganese accumulation causes cytoplasmic manganese accumulation that would otherwise cause oxidative stress and mitochondrial dysfunction [@kett2015]. PMID: 41944191

Autophagy and Lysosomal Function

ATP13A2 is a key regulator of the autophagy-lysosomal pathway, which is essential for clearing protein aggregates, damaged organelles, and cellular debris [@sato2018]. Loss of ATP13A2 function impairs autophagic flux and leads to reduced cathepsin activity and impaired lysosomal function [@kelley2021]. Importantly, impaired autophagy results in decreased clearance of alpha-synuclein, promoting its aggregation—a hallmark of PD pathology [@gomes2019]. PMID: 41935079

Mitochondrial Quality Control

Emerging evidence suggests ATP13A2 is involved in mitochondrial quality control through its interactions with the PINK1-Parkin pathway [@siddiqui2022]. ATP13A2 deficiency leads to mitochondrial membrane potential loss, increased reactive oxygen species (ROS) production, impaired mitophagy, and reduced mitochondrial bioenergetic capacity [@siddiqui2022].

Disease Associations

Kufor-Rakeb Syndrome (PARK9)

Kufor-Rakeb syndrome (KRS) is an autosomal recessive neurodegenerative disorder caused by biallelic loss-of-function mutations in ATP13A2 [@schmitt2010]. The syndrome was first described in a Jordanian family from the Kufor-Rakeb region and is characterized by early-onset parkinsonism, levodopa responsiveness, pyramidal signs, supranuclear gaze palsy, cognitive decline, and brain iron accumulation [@ramonet2012].

Parkinson's Disease

While KRS is caused by complete loss of ATP13A2 function, more common genetic variants in ATP13A2 have been associated with sporadic Parkinson's disease risk [@gualandi2021]. ATP13A2 variants may confer risk through subtle impairment of lysosomal function [@zhang2017].

Neuronal Ceroid Lipofuscinosis (NCL)

Recessive ATP13A2 mutations can cause a form of NCL characterized by lysosomal storage of lipofuscin-like material, progressive visual loss, seizures, developmental regression, and childhood onset [@usenkar2019].

Animal Models

Several animal models have been developed to study ATP13A2 function [@matsui2013; @ferris2020]. Global and conditional knockouts demonstrate motor deficits and alpha-synuclein pathology [@ferris2020]. Drosophila loss of ATP13A2 homolog leads to neurodegeneration and shortened lifespan [@chen2019].

Pathophysiology

Lysosomal Storage Dysfunction

Loss of ATP13A2 function leads to progressive lysosomal storage abnormalities including lipofuscin accumulation, autophagic vacuoles, lysosomal membrane expansion, and impaired cargo degradation [@kelley2021]. These storage abnormalities are reminiscent of neuronal ceroid lipofuscinoses, explaining the phenotypic overlap [@usenkar2019].

Metal Homeostasis Disruption

ATP13A2 deficiency causes widespread metal dysregulation with manganese accumulation in cytosol and mitochondria, altered synaptic zinc handling, and increased free iron leading to Fenton chemistry [@tanaka2022].

Mitochondrial Pathology

Mitochondrial abnormalities in ATP13A2 deficiency include complex I deficiency, membrane potential loss, ROS overproduction, mitochondrial DNA mutations accumulation, and enhanced apoptosis susceptibility [@siddiqui2022].

Protein Aggregation

ATP13A2 loss promotes aggregation of several proteins relevant to PD, particularly alpha-synuclein [@gomes2019]. The bidirectional relationship between ATP13A2 and alpha-synuclein is particularly significant, with each protein's aggregation promoting the other's pathology [@gomes2019; @orenstein2020].

Neuroinflammation

ATP13A2 deficiency triggers robust neuroinflammatory responses including microglial activation, elevated cytokine release (IL-1β, TNF-α, IL-6), complement activation, and NLRP3 inflammasome activation [@zhou2023].

Research Models

Patient fibroblasts show elevated lysosomal pH and impaired autophagy [@nguyen2019]. iPSC-derived neurons demonstrate mitochondrial dysfunction [@nguyen2019].

Therapeutic Implications

ATP13A2 represents a promising therapeutic target for PD [@zhang2021]. AAV-mediated delivery of ATP13A2 could restore function in patients with loss-of-function mutations, while small molecule activators could benefit patients with partial loss of function @zhang2021].

Summary

ATP13A2 (PARK9) encodes a lysosomal P5B-type ATPase critical for metal cation transport, lysosomal function, and neuronal survival [@kett2015]. Biallelic mutations cause Kufor-Rakeb syndrome, an early-onset parkinsonism with additional neurological features [@schmitt2010]. The protein plays essential roles in lysosomal manganese and zinc transport, autophagy and protein clearance, mitochondrial quality control, and metal homeostasis @kett2015]. Understanding ATP13A2 function provides insights into the broader pathogenesis of Parkinson's disease and identifies potential therapeutic targets @zhang2021].

Pathway Diagram

The following diagram shows the key molecular relationships involving ATP13A2 — ATPase Cation Transporting 13A2 discovered through SciDEX knowledge graph analysis:

References